Real-world comparison of drug-eluting and bare-metal stents in superficial femoral artery occlusive disease with trans-Atlantic intersociety consensus B lesions: A 2-year, single-institute study

Fan Chieh Meng, Po Lin Chen, Chiu Yang Lee, Chun Che Shih, I. Ming Chen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Endovascular stenting has surpassed bypass surgery to become the first-line treatment for superficial femoral artery (SFA) occlusive disease, and various types of stents including bare-metal stents (BMSs), covered stents, and drug-eluting stents (DESs), have been approved for treatment. This retrospective, single-institute study compared the short-term, real-world outcomes of BMSs and DESs for treating SFA occlusive disease. Methods: A retrospective chart review was used to enroll 94 patients who received a DES (n = 24) or BMS (n = 70) between 2009 and 2014. All patients had SFA occlusive disease with critical limb ischemia and an intermediate length of SFA occlusion [Trans-Atlantic Intersociety Consensus (TASC)-II B lesions] and were regularly followed for 2 years. All patient characteristics, procedural details, and outcomes were recorded. Result: The 1-year primary patency rates in the BMS and DES groups were 71.4% and 87.5% (p = 0.169), respectively, and the corresponding 2-year rates were 61.4% and 79.2% (p = 0.139). The target lesion revascularization rate was 38.6% versus 20.8% (p = 0.139), the in-stent restenosis rate was 22.9% versus 0% (p = 0.009), the major limb amputation rate was 4.3% versus 0% (p = 0.568), the peripheral arterial disease-related mortality rate was 8.6% versus 0% (p = 0.332), and the all-cause mortality rate was 11.4% versus 0% (p = 0.109), respectively. Conclusions: The 2-year results revealed higher safety, superior efficacy, and greater clinical benefits of DESs than BMSs for treating TASC-II B SFA occlusive disease. However, more cases and long-term follow-up are warranted.

Original languageEnglish
Pages (from-to)130-136
Number of pages7
JournalActa Cardiologica Sinica
Volume34
Issue number2
DOIs
Publication statusPublished - Mar 1 2018
Externally publishedYes

Fingerprint

Femoral Artery
varespladib methyl
Stents
Metals
Drug-Eluting Stents
Pharmaceutical Preparations
Extremities
Mortality
Peripheral Arterial Disease
Amputation
Ischemia
Safety
Therapeutics

Keywords

  • Bare-metal stent
  • Drug-eluting stent
  • Superficial femoral artery
  • Trans-Atlantic Intersociety Consensus (TASC)-II B superficial femoral artery lesion

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Real-world comparison of drug-eluting and bare-metal stents in superficial femoral artery occlusive disease with trans-Atlantic intersociety consensus B lesions : A 2-year, single-institute study. / Meng, Fan Chieh; Chen, Po Lin; Lee, Chiu Yang; Shih, Chun Che; Chen, I. Ming.

In: Acta Cardiologica Sinica, Vol. 34, No. 2, 01.03.2018, p. 130-136.

Research output: Contribution to journalArticle

@article{5d8ea00910a24ed593ffe75f88844acd,
title = "Real-world comparison of drug-eluting and bare-metal stents in superficial femoral artery occlusive disease with trans-Atlantic intersociety consensus B lesions: A 2-year, single-institute study",
abstract = "Background: Endovascular stenting has surpassed bypass surgery to become the first-line treatment for superficial femoral artery (SFA) occlusive disease, and various types of stents including bare-metal stents (BMSs), covered stents, and drug-eluting stents (DESs), have been approved for treatment. This retrospective, single-institute study compared the short-term, real-world outcomes of BMSs and DESs for treating SFA occlusive disease. Methods: A retrospective chart review was used to enroll 94 patients who received a DES (n = 24) or BMS (n = 70) between 2009 and 2014. All patients had SFA occlusive disease with critical limb ischemia and an intermediate length of SFA occlusion [Trans-Atlantic Intersociety Consensus (TASC)-II B lesions] and were regularly followed for 2 years. All patient characteristics, procedural details, and outcomes were recorded. Result: The 1-year primary patency rates in the BMS and DES groups were 71.4{\%} and 87.5{\%} (p = 0.169), respectively, and the corresponding 2-year rates were 61.4{\%} and 79.2{\%} (p = 0.139). The target lesion revascularization rate was 38.6{\%} versus 20.8{\%} (p = 0.139), the in-stent restenosis rate was 22.9{\%} versus 0{\%} (p = 0.009), the major limb amputation rate was 4.3{\%} versus 0{\%} (p = 0.568), the peripheral arterial disease-related mortality rate was 8.6{\%} versus 0{\%} (p = 0.332), and the all-cause mortality rate was 11.4{\%} versus 0{\%} (p = 0.109), respectively. Conclusions: The 2-year results revealed higher safety, superior efficacy, and greater clinical benefits of DESs than BMSs for treating TASC-II B SFA occlusive disease. However, more cases and long-term follow-up are warranted.",
keywords = "Bare-metal stent, Drug-eluting stent, Superficial femoral artery, Trans-Atlantic Intersociety Consensus (TASC)-II B superficial femoral artery lesion",
author = "Meng, {Fan Chieh} and Chen, {Po Lin} and Lee, {Chiu Yang} and Shih, {Chun Che} and Chen, {I. Ming}",
year = "2018",
month = "3",
day = "1",
doi = "10.6515/ACS.201803_34(2).20171126A",
language = "English",
volume = "34",
pages = "130--136",
journal = "Acta Cardiologica Sinica",
issn = "1011-6842",
publisher = "Republic of China Society of Cardiology",
number = "2",

}

TY - JOUR

T1 - Real-world comparison of drug-eluting and bare-metal stents in superficial femoral artery occlusive disease with trans-Atlantic intersociety consensus B lesions

T2 - A 2-year, single-institute study

AU - Meng, Fan Chieh

AU - Chen, Po Lin

AU - Lee, Chiu Yang

AU - Shih, Chun Che

AU - Chen, I. Ming

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Background: Endovascular stenting has surpassed bypass surgery to become the first-line treatment for superficial femoral artery (SFA) occlusive disease, and various types of stents including bare-metal stents (BMSs), covered stents, and drug-eluting stents (DESs), have been approved for treatment. This retrospective, single-institute study compared the short-term, real-world outcomes of BMSs and DESs for treating SFA occlusive disease. Methods: A retrospective chart review was used to enroll 94 patients who received a DES (n = 24) or BMS (n = 70) between 2009 and 2014. All patients had SFA occlusive disease with critical limb ischemia and an intermediate length of SFA occlusion [Trans-Atlantic Intersociety Consensus (TASC)-II B lesions] and were regularly followed for 2 years. All patient characteristics, procedural details, and outcomes were recorded. Result: The 1-year primary patency rates in the BMS and DES groups were 71.4% and 87.5% (p = 0.169), respectively, and the corresponding 2-year rates were 61.4% and 79.2% (p = 0.139). The target lesion revascularization rate was 38.6% versus 20.8% (p = 0.139), the in-stent restenosis rate was 22.9% versus 0% (p = 0.009), the major limb amputation rate was 4.3% versus 0% (p = 0.568), the peripheral arterial disease-related mortality rate was 8.6% versus 0% (p = 0.332), and the all-cause mortality rate was 11.4% versus 0% (p = 0.109), respectively. Conclusions: The 2-year results revealed higher safety, superior efficacy, and greater clinical benefits of DESs than BMSs for treating TASC-II B SFA occlusive disease. However, more cases and long-term follow-up are warranted.

AB - Background: Endovascular stenting has surpassed bypass surgery to become the first-line treatment for superficial femoral artery (SFA) occlusive disease, and various types of stents including bare-metal stents (BMSs), covered stents, and drug-eluting stents (DESs), have been approved for treatment. This retrospective, single-institute study compared the short-term, real-world outcomes of BMSs and DESs for treating SFA occlusive disease. Methods: A retrospective chart review was used to enroll 94 patients who received a DES (n = 24) or BMS (n = 70) between 2009 and 2014. All patients had SFA occlusive disease with critical limb ischemia and an intermediate length of SFA occlusion [Trans-Atlantic Intersociety Consensus (TASC)-II B lesions] and were regularly followed for 2 years. All patient characteristics, procedural details, and outcomes were recorded. Result: The 1-year primary patency rates in the BMS and DES groups were 71.4% and 87.5% (p = 0.169), respectively, and the corresponding 2-year rates were 61.4% and 79.2% (p = 0.139). The target lesion revascularization rate was 38.6% versus 20.8% (p = 0.139), the in-stent restenosis rate was 22.9% versus 0% (p = 0.009), the major limb amputation rate was 4.3% versus 0% (p = 0.568), the peripheral arterial disease-related mortality rate was 8.6% versus 0% (p = 0.332), and the all-cause mortality rate was 11.4% versus 0% (p = 0.109), respectively. Conclusions: The 2-year results revealed higher safety, superior efficacy, and greater clinical benefits of DESs than BMSs for treating TASC-II B SFA occlusive disease. However, more cases and long-term follow-up are warranted.

KW - Bare-metal stent

KW - Drug-eluting stent

KW - Superficial femoral artery

KW - Trans-Atlantic Intersociety Consensus (TASC)-II B superficial femoral artery lesion

UR - http://www.scopus.com/inward/record.url?scp=85044768645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044768645&partnerID=8YFLogxK

U2 - 10.6515/ACS.201803_34(2).20171126A

DO - 10.6515/ACS.201803_34(2).20171126A

M3 - Article

AN - SCOPUS:85044768645

VL - 34

SP - 130

EP - 136

JO - Acta Cardiologica Sinica

JF - Acta Cardiologica Sinica

SN - 1011-6842

IS - 2

ER -